GLAXO WELLCOME EPIVIR/RETROVIR FIXED-DOSE COMBO TABLET FILING "IMMINENT" FOR HIV, COMPANY SAYS; ABACAVIR NUCLEOSIDE ANALOGUE NDA PLANNED FOR 1998
Executive Summary
Glaxo Wellcome is preparing to file an NDA for a twice-daily fixed-dose combination of its two nucleoside analogue anti-HIV treatments, Retrovir (zidovudine) and Epivir (lamivudine).